←back to thread

Type 2 diabetes: New treatment eliminates insulin for 86% of patients

(scitechdaily.com)
196 points amichail | 1 comments | 17 Oct 24 20:46 UTC | HN request time: 0s | source
Show context
janice1999 ◴[17 Oct 24 21:24 UTC] No.41873971[source]▶
Paper: https://pubmed.ncbi.nlm.nih.gov/38692517/

> Recellularization via electroporation therapy (ReCET) is a novel endoscopic procedure that uses electroporation to induce cellular apoptosis and subsequent reepithelization.

replies(1): >>41873977 #
arcticbull ◴[17 Oct 24 21:26 UTC] No.41873977[source]▶
... plus GLP-1.

GLP-1s baseline eliminate insulin for about ~40% of people. This boosts that number to 86%.

Note that Tirzepatide also reduces the chance of developing type 2 in the first place by 94%, and I suspect that newer generation receptor agonists will see higher insulin discontinuation rates in general.

Very cool stuff all around. Might finally be able to put this whole obesity-and-diabetes thing to bed.

replies(1): >>41874242 #
metadat ◴[17 Oct 24 21:58 UTC] No.41874242[source]▶
Tirzepatide side effects sound pretty nasty, though less so than dying in a diabetic coma.

https://en.wikipedia.org/wiki/Tirzepatide

replies(3): >>41874264 #>>41874320 #>>41874776 #
1. tssva ◴[17 Oct 24 22:10 UTC] No.41874320[source]▶
The side effects are usually short lived. I'm on tirzepatide and had some mild digestive issues for the 1st 3 - 4 weeks and haven't had any since then. My side effects when starting metformin were worse.